Literature DB >> 23675561

Immune surveillance and lymphoid malignancy in immunocompromised host.

Patrick L Stevens1, Nishitha M Reddy.   

Abstract

Immune surveillance is a dynamic process that involves an intact immune system to identify and protect the host against tumor development. The increased understanding of the genetics, infections and hematological malignancies in congenital immune deficiency states supports the concept that impaired T cells and Natural-killer/T cells leads to B-cell lymphoma. Furthermore, severe combined immunodeficient mice are prone to spontaneous tumor development and therefore serve as experimental models. Here we discuss the acquired conditions and mechanisms involved in dysregulation of the immune system that lead to lymphoma. Preemptive strategies to improve immune regulation and response and restore a competent immune system may lead to a decrease in lymphoid malignancies.

Entities:  

Keywords:  Lymphoma; immune deficiency; immune surveillance

Year:  2013        PMID: 23675561      PMCID: PMC3649811     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  76 in total

1.  A gene polymorphism associated with posttransplant lymphoproliferative disorder.

Authors:  A M VanBuskirk; V Malik; D Xia; R P Pelletier
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

2.  Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes.

Authors:  N Burdin; C Van Kooten; L Galibert; J S Abrams; J Wijdenes; J Banchereau; F Rousset
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

3.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

4.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

5.  Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma.

Authors:  Martin Stern; Gerhard Opelz; Bernd Döhler; Christoph Hess
Journal:  Blood       Date:  2010-03-05       Impact factor: 22.113

6.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

7.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

8.  Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints.

Authors:  B Gruhne; R Sompallae; M G Masucci
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

9.  TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma.

Authors:  Marcel Batten; Carrie Fletcher; Lai Guan Ng; Joanna Groom; Julie Wheway; Yacine Laâbi; Xiaoguan Xin; Pascal Schneider; Jurg Tschopp; Charles R Mackay; Fabienne Mackay
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

10.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden.

Authors:  J Adami; H Gäbel; B Lindelöf; K Ekström; B Rydh; B Glimelius; A Ekbom; H-O Adami; F Granath
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  2 in total

1.  Guillain-Barré syndrome and severe infection following chemotherapy for peripheral T-cell lymphoma: A case report.

Authors:  Yang-Yang Ma; Lei Zhang; DA-Liang Zhang; Wen-Shuo Liu
Journal:  Oncol Lett       Date:  2014-09-16       Impact factor: 2.967

2.  Malignancies, Particularly B-Cell Lymphomas, Are a Frequent Cause of Mortality in Human Immunodeficiency Virus-1 Patients Despite Highly Active Antiretroviral Therapy.

Authors:  Daniel O Griffin; Michael Metzger; Kaitlin Poeth; Kathy Deng; Arif Dharsee; Juan Carlos Rico; Joseph McGowan
Journal:  Open Forum Infect Dis       Date:  2015-09-30       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.